Development
Boston Scientific Corporation
BSX
$105.41
$0.490.47%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 1.59B | 1.23B | 912.00M | 902.00M | 698.00M |
| Total Depreciation and Amortization | 1.20B | 1.18B | 1.16B | 1.15B | 1.14B |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 485.00M | 327.00M | 559.00M | 571.00M | 697.00M |
| Change in Net Operating Assets | -770.00M | -379.00M | -507.00M | -846.00M | -1.01B |
| Cash from Operations | 2.50B | 2.35B | 2.13B | 1.77B | 1.53B |
| Capital Expenditure | -711.00M | -656.00M | -616.00M | -578.00M | -588.00M |
| Sale of Property, Plant, and Equipment | 4.00M | 6.00M | 6.00M | 7.00M | 12.00M |
| Cash Acquisitions | -1.81B | -1.02B | -1.09B | -446.00M | -1.54B |
| Divestitures | -- | 5.00M | 5.00M | 5.00M | 5.00M |
| Other Investing Activities | -56.00M | -41.00M | -38.00M | 91.00M | 102.00M |
| Cash from Investing | -2.57B | -1.70B | -1.73B | -921.00M | -2.01B |
| Total Debt Issued | 0.00 | 0.00 | -117.00M | -224.00M | 3.27B |
| Total Debt Repaid | -4.00M | -4.00M | -1.00M | -1.00M | -3.44B |
| Issuance of Common Stock | 182.00M | 184.00M | 168.00M | 147.00M | 136.00M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -28.00M | -41.00M | -55.00M | -55.00M | -55.00M |
| Other Financing Activities | -145.00M | -148.00M | -219.00M | -478.00M | -464.00M |
| Cash from Financing | 5.00M | -9.00M | -224.00M | -611.00M | -548.00M |
| Foreign Exchange rate Adjustments | -4.00M | -5.00M | -6.00M | -9.00M | -9.00M |
| Miscellaneous Cash Flow Adjustments | 0.00 | 1.00M | -1.00M | 1.00M | 0.00 |
| Net Change in Cash | -70.00M | 636.00M | 162.00M | 234.00M | -1.04B |